FDA approves Dupixent for treatment of chronic sinusitis in adults

recently, the U.SFDA(http://approved Dupixent (Dupilumab) to treat chronic sinusitis (long-term inflammation of the sinus and nasal cavity) in adults with nasal polyps (growth in the inner wall of the sinus)previously, Dupixent was granted FDA-granted "priority review" statusDupixent's safety and efficacy were determined by injection, two studies of 724 patients with chronic sinusitis and nasal polyps aged 18 and olderDespite taking nasal corticosteroids, these patients still have symptomscompared to the placebo group, patients taking Dupixent had a statistically significant reduction in nasal polyps and nasal congestionIn addition, patients also reported increased sense of smell and reduced demand for nasal polyps surgery and oral steroidssafetynote that Dupixent can cause severe allergic reactions and eye problems such as eye inflammation (conjunctivitis) and corneal inflammation (keratitis)If the patient develops new or worsening eye symptoms, such as redness, itching, pain, or changes in vision,promptly consult a(http://a doctorThe most common side effects include reactions at the injection site and inflammation of the eyes and eyelids, including redness, swelling and itchingPatients using Dupixent should avoid a live vaccine